viiV

ViiV Healthcare, commonly referred to as ViiV, is a British multinational pharmaceutical company focused on HIV treatment and prevention. It was established in 2009 as a joint venture formed by GlaxoSmithKline (GSK), Pfizer, and Shionogi. The company is headquartered in London and operates globally, developing and marketing antiretroviral medicines for adults and children, as well as preventive therapies.

ViiV’s portfolio includes several widely used HIV medicines and regimens. Notable products include Tivicay (dolutegravir), Triumeq (abacavir/lamivudine/dolutegravir), and Dovato (dolutegravir/lamivudine). The company has also developed long-acting injectable regimens, such as Cabenuva (cabotegravir and rilpivirine as a maintenance therapy) and Apretude (cabotegravir for HIV pre-exposure prophylaxis, PrEP). ViiV continues to pursue research into long-acting formulations, two-drug regimens, and pediatric options to improve adherence and outcomes.

Ownership and governance are led by GSK, with Pfizer and Shionogi holding minority interests. As a specialty pharmaceutical company, ViiV collaborates with academic, clinical, and industry partners to advance HIV treatment and prevention options, including formulations that reduce dosing frequency and improve patient quality of life. The enterprise position emphasizes innovation in antiretroviral therapy and global access to effective HIV care.